Cascadian Therapeutics, Inc.
CASC
CASC was delisted on the 8th of March, 2018.
1 hedge funds and large institutions have $0 invested in Cascadian Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 90 closing their positions.
99% less funds holding
Funds holding: 91 → 1 (-90)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $152M → $0 (-$152M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 90
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$33.5M |
| 2 |
BG
Baupost Group
Boston,
Massachusetts
|
-$32.3M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$11.6M |
| 4 |
BlackRock
New York
|
-$10.1M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$9.2M |
CASC Hedge Fund Activity: Q1 2018 in Review
1 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q1 2018, worth a combined $0 — down 100% from $152M a quarter earlier.
Sellers outnumbered buyers: 90 funds closed out of CASC and 0 opened new positions — a net loss of 90 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was NEA Management Company, exiting entirely with an estimated $33.5M sold.
- 1 institutional investor held Cascadian Therapeutics, Inc. (CASC) as of Q1 2018, down from 91 in Q4 2017.
- Funds reported $0 of Cascadian Therapeutics, Inc. stock for Q1 2018, down 100% quarter-over-quarter.
- 0 funds opened new Cascadian Therapeutics, Inc. positions in Q1 2018 and 90 closed out, a net change of -90 holders.
- The largest Cascadian Therapeutics, Inc. seller in Q1 2018 was NEA Management Company, an estimated $33.5M sold.
Based on aggregated 13F filings for Q1 2018.